…
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 135.23M | -212.36M | -180.12M | -146.02M | -34.38M |
| Net income | 124.34M | -211.84M | -180.55M | -145.44M | -36.56M |
| Selling general administrative | 73.36M | 42.56M | 57.88M | 64.18M | 29.46M |
| Gross profit | 412.48M | 26.68M | 38.95M | 29.54M | 53.02M |
| Reconciled depreciation | 12.00M | 12.22M | 10.28M | 7.33M | 3.63M |
| Ebit | 118.52M | -225.22M | -197.75M | -151.30M | -36.76M |
| Ebitda | 130.53M | -215.63M | -187.47M | -149.76M | -33.13M |
| Depreciation and amortization | 12.00M | 9.58M | 10.28M | 1.54M | 3.63M |
| Non operating income net other | - | 1.31M | 7.34M | 5.28M | -1.09M |
| Operating income | 130.53M | -215.63M | -187.47M | -151.30M | -33.13M |
| Other operating expenses | 281.95M | 242.31M | 226.42M | 180.08M | 86.15M |
| Interest expense | 3.60M | 12.86M | 17.62M | 11.08M | 0.17M |
| Tax provision | 10.89M | -0.52M | 0.43M | -0.58M | 2.17M |
| Interest income | 3.60M | 2.51M | 5.70M | 6.02M | 2.64M |
| Net interest income | 3.60M | 2.51M | 5.70M | 6.02M | 2.47M |
| Extraordinary items | - | - | - | -0.01M | -0.00M |
| Non recurring | - | - | - | 0.77M | - |
| Income tax expense | 10.89M | -0.52M | 0.43M | -0.58M | 2.17M |
| Total revenue | 412.48M | 26.68M | 38.95M | 29.54M | 53.02M |
| Total operating expenses | 281.95M | 242.31M | 226.42M | 180.08M | 86.15M |
| Cost of revenue | - | - | - | 115.90M | 56.93M |
| Total other income expense net | 4.71M | 3.27M | 7.34M | 5.28M | -1.26M |
| Net income from continuing ops | 124.34M | -211.84M | -180.55M | -145.44M | -36.56M |
| Net income applicable to common shares | 124.34M | -211.84M | -180.55M | -145.44M | -36.56M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 463.09M | 580.88M | 648.73M | 389.13M | 538.38M |
| Intangible assets | 4.58M | 25.28M | 26.38M | 21.47M | 22.93M |
| Other current assets | 18.86M | 19.12M | 19.07M | 20.00M | 13.43M |
| Total liab | 124.32M | 116.07M | 155.77M | 140.04M | 128.45M |
| Total stockholder equity | 338768.00M | 464.81M | 492.96M | 249.09M | 409.92M |
| Deferred long term liab | - | - | 17.64M | 34.51M | 34.12M |
| Other current liab | 49.71M | 41.59M | 82.09M | 7.78M | 39.30M |
| Common stock | 1015618.00M | 1006.57M | 906.76M | 741.15M | 724.22M |
| Capital stock | 1023.81M | 1006.57M | 906.76M | 741.15M | 724.22M |
| Retained earnings | -830335.00M | -677.44M | -558.76M | -683.10M | -471.26M |
| Other liab | - | - | 35.35M | 37.26M | 36.98M |
| Good will | 12.02M | 12.02M | 12.02M | 12.02M | 12.02M |
| Other assets | -162477.36M | - | 34.71M | 34.40M | 65.81M |
| Cash | 66103.00M | 157.56M | 400.91M | 201.87M | 242.04M |
| Total current liabilities | 88.29M | 55.76M | 95.62M | 71.85M | 85.67M |
| Current deferred revenue | 25.59M | 3.70M | 2.35M | 57.59M | 37.41M |
| Net debt | -47625.00M | -130.84M | -372.80M | -169.53M | -233.39M |
| Short term debt | 2.74M | 4.26M | 3.32M | 1.31M | 2.71M |
| Short long term debt total | 18478.00M | 26.72M | 28.11M | 32.33M | 8.64M |
| Other stockholder equity | 160437.00M | 142.27M | 151.61M | 197.71M | 163.62M |
| Property plant equipment | - | - | 47.65M | 22.78M | 12.19M |
| Total current assets | 300.45M | 412.93M | 544.71M | 288.22M | 455.08M |
| Long term investments | 98.43M | 82.15M | 0.89M | 0.89M | 25.92M |
| Net tangible assets | - | - | 472.19M | 215.61M | 374.98M |
| Short term investments | 159.67M | 216.77M | 91.32M | 50.74M | 184.32M |
| Net receivables | 55.81M | 19.48M | 33.40M | 15.61M | 15.29M |
| Inventory | - | 0.00M | - | - | - |
| Accounts payable | 3.90M | 6.21M | 7.86M | 5.17M | 6.24M |
| Accumulated other comprehensive income | -6952.00M | -6.60M | -6.66M | -6.66M | -6.66M |
| Common stock total equity | - | - | - | 741.15M | 724.22M |
| Retained earnings total equity | - | - | - | -683.10M | -471.26M |
| Non currrent assets other | 8.92M | 7.35M | 15.74M | 13.70M | 3.10M |
| Non current assets total | 162.64M | 167.95M | 104.02M | 100.91M | 83.30M |
| Capital lease obligations | 18.51M | 26.72M | 28.11M | 41.23M | 8.64M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -53.85M | 157.88M | -37.17M | -11.71M | -105.63M |
| Change to liabilities | 26.48M | 16.48M | 7.62M | 21.27M | 3.82M |
| Total cashflows from investing activities | -53.85M | 144.60M | -43.44M | -25.59M | -109.05M |
| Net borrowings | -0.01M | -0.02M | -0.04M | -0.02M | -0.01M |
| Total cash from financing activities | 108.58M | 8.01M | 308.98M | 193.66M | 91.43M |
| Change to operating activities | -5.79M | -15.82M | -4.66M | -9.47M | -0.25M |
| Net income | 124.34M | -211.84M | -180.55M | -145.44M | -36.56M |
| Change in cash | 199.04M | -40.17M | 113.58M | 86.25M | 6.26M |
| Begin period cash flow | 201.87M | 242.04M | 128.45M | 42.20M | 35.95M |
| End period cash flow | 400.91M | 201.87M | 242.04M | 128.45M | 42.20M |
| Total cash from operating activities | 144.11M | -192.45M | -151.40M | -81.85M | 24.18M |
| Issuance of capital stock | 107.53M | 0.00M | 300.91M | 188.23M | 90.75M |
| Depreciation | 12.00M | 9.58M | 10.28M | 7.33M | 3.63M |
| Other cashflows from investing activities | - | -0.88M | -1.96M | -7.56M | -2.62M |
| Dividends paid | - | - | -1.11M | -0.60M | - |
| Change to inventory | - | - | - | -9.77M | -0.11M |
| Change to account receivables | -17.51M | -0.27M | -13.11M | -1.83M | -0.12M |
| Sale purchase of stock | 1.40M | 2.07M | 1.11M | 0.60M | 91.43M |
| Other cashflows from financing activities | -0.34M | 5.96M | 8.11M | 5.45M | 0.69M |
| Change to netincome | 3.75M | 9.20M | 28.93M | 49.54M | 16.94M |
| Capital expenditures | 13.12M | 13.29M | 6.26M | 13.88M | 3.42M |
| Change receivables | - | -0.27M | -13.11M | -1.83M | -0.12M |
| Cash flows other operating | - | -12.55M | -1.81M | -10.83M | 36.46M |
| Cash and cash equivalents changes | - | -39.84M | 114.14M | 86.22M | 6.56M |
| Change in working capital | 4.01M | 0.39M | -10.15M | 6.44M | 39.92M |
| Stock based compensation | 4.01M | 10.76M | 29.12M | 49.00M | 13.44M |
| Other non cash items | -2.21M | -0.39M | -0.36M | 1.54M | 3.75M |
| Free cash flow | 130.98M | -205.74M | -157.67M | -95.73M | 20.76M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ZYME Zymeworks Inc. Common Stock |
0.57 2.19% |
26.61 | - | - | 8.74 | 2.51 | 6.09 | 0.34 |
| NVO Novo Nordisk A/S |
-0.34 0.86% |
39.09 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-6.95 1.30% |
529.50 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-18.50 1.96% |
927.03 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
| Name | Title | Year Born |
|---|---|---|
| Mr. Neil A. Klompas C.A., CPA, CA, CPA | Pres & COO | 1972 |
| Dr. Ali Tehrani Ph.D. | Advisor | 1972 |
| Dr. Neil Josephson M.D. | Chief Medical Officer | 1961 |
| Mr. Kenneth H. Galbraith C.A. | CEO & Chairman | 1963 |
| Dr. Christopher Astle Ph.D. | Sr. VP & CFO | 1980 |
| Dr. Paul Moore Ph.D. | Chief Scientific Officer | NA |
| Jack W. Spinks | Mang. of Investor Relations | NA |
| Mr. Daniel Dex J.D., Ph.D. | VP of Legal & Corp. Sec. | NA |
| Mr. Mark Hollywood | Sr. VP of Technical & Manufacturing Operations | 1970 |
| Dr. David Poon Ph.D. | VP of Bus. Devel. and Alliance Management | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.